An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
NCT ID: NCT04950114
Last Updated: 2022-11-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
31 participants
INTERVENTIONAL
2021-07-27
2022-11-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
NCT04387448
Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
NCT02197767
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
NCT00464321
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
NCT01665391
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
NCT06664814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
200 mg Dose Cohort
Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level.
GFB-887
GFB-887 is a potent, small molecule inhibitor of TRPC5.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GFB-887
GFB-887 is a potent, small molecule inhibitor of TRPC5.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who enrolled in any other interventional study during the time between completion of the prior GFB-887 interventional study and this study may be considered for enrollment following consultation with the Medical Monitor.
Exclusion Criteria
* Participant has an unstable medical condition based on medical history, physical examination, laboratory tests, ECGs, vital signs or is otherwise unstable in the judgement of the Investigator which would pose a risk to the participant or interfere with study evaluation, procedures, or completion
* Evidence of significant hypersensitivity, intolerance, or allergy to any component of investigational product GFB-887
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Goldfinch Bio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Academic Medical Research Institute (AMRI)
Los Angeles, California, United States
Amicis Research Center
Northridge, California, United States
Kidney and Hypertension Center - Apple Valley
Victorville, California, United States
University of Colorado Anschutz Medical Center
Aurora, Colorado, United States
Colorado Kidney Care (Denver Nephrology)
Denver, Colorado, United States
Boise Kidney and Hypertension Institute
Nampa, Idaho, United States
NANI Research, LLC
Hinsdale, Illinois, United States
St. Clair Nephrology
Roseville, Michigan, United States
Clinical Research Consultants
Kansas City, Missouri, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Southeast Renal Research Institute
Chattanooga, Tennessee, United States
Prolato Clinical Research Center
Houston, Texas, United States
Clinical Advancement Center, PLLC
San Antonio, Texas, United States
Tranquility Research
Webster, Texas, United States
Utah Kidney Center
Salt Lake City, Utah, United States
Providence Medical Research Center
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GFB-887-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.